Company / R&D Expense
MANNKIND CORP R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$66.3M
FY2025
5-year range
$12.3M / $66.3M
FY2021-FY2025
Trend
+44.6%
vs FY2024
Sector context
#169 of 209
Health Care
What the data says
MANNKIND CORP's r&d expense of $66M is lower than 81% of companies in the Health Care sector (FY2025). R&D Expense has increased for 5 consecutive years, from $6M in FY2020 to $66M in FY2025.
Based on SEC 10-K filings.
$66M in FY2025 with a 5-year CAGR of +60.4%.
Improved from $31M to $66M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +49.8%
- 5-Year CAGR
- +60.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 209This company $66.3M Sector average $647.6M
▼
-89.8% below sector average
Key checks
Key Insights
- MANNKIND CORP's r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +60.4%, indicating consistent growth.
- In FY2025, r&d expense increased 44.6% year-over-year.
- Ranks #169 out of 209 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -2.74 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $66.3M | +44.6% |
| FY2024 | $45.9M | +46.7% |
| FY2023 | $31.3M | +58.6% |
| FY2022 | $19.7M | +60.2% |
| FY2021 | $12.3M | +97.1% |
| FY2020 | $6.2M | -9.4% |
| FY2019 | $6.9M | -21.0% |
| FY2018 | $8.7M | -38.1% |
| FY2017 | $14.1M | -5.4% |
| FY2016 | $14.9M | -49.7% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026